Abstract
Despite the compelling relationship between early treatment and outcome from reperfusion therapy in patients with acute myocardial infarction, significant delays in early treatment are imposed by the patient, prehospital systems, and hospital processes and protocols used in the identification and treatment of patients with myocardial infarction. A survey instrument designed to determine the prevalence of hospital policies and protocols that might delay or expedite treatment with thrombolytic therapy in patients with acute myocardial infarction was completed by 524 hospitals participating in the National Registry for Myocardial Infarction (NRMI). Participating hospitals had treated 17,646 patients with tissue plasminogen activator. The door to drug time for the entire population of patients treated at each hospital was available. Door to drug times were compared between those hospitals that had a positive response to a policy and those that had a negative response to that policy. Among respondent hospitals, thrombolysis was excluded by protocol in 34.4% for age above 75 and in 55% for presentation after 6 hours of chest pain onset. Furthermore, 29.4% of hospitals required routine laboratory testing other than electrocardiography (ECG), including chest x-ray, prior to determination of eligibility for thrombolysis. Door to drug times were shorter in those hospitals with prehospital 12-lead ECG availability, assessment of the 12-lead ECG by the emergency department nurse and physician as soon as it was available, and initiation of thrombolysis by the emergency physician (in patients with clear-cut ST elevation myocardial infarction) without bedside cardiology consultation. Door to drug times were longer in those hospitals in which predecision laboratory results were required, written informed consent was mandated, and drug was initiated in the cardiac intensive care unit rather than in the emergency department itself. Door to drug times were not significantly different in those hospitals with a designated chest pain center compared with those operating under a focused patient care protocol. We conclude that the earliest possible hospital treatment of acute myocardial infarction patients may be precluded by multiple components of emergency department policies and process, many of them inappropriate for safe, efficient, and effective identification and management of these patients.
Similar content being viewed by others
References
Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med 1990;322:743–753.
The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl Med 1983;309:331–336.
Reimer KA, Lowe JE, Rasmussen MM, et al. The wave-front phenomenon of ischemic cell death, 1: Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786–794.
Bergmann SR, Lerch RA, Fox KAA, et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by position tomography. Am J Med 1982;73:573–581.
Gruppo Italiano per lo Studio della Streptochinase nell'Infarcto miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–402.
ISIS-2 (Second International Study of Infarct Survival Collaborative Group). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.
Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311–322.
Simes J, Ross AM, Simoons M, Van der Werf F, Topol EJ for the GUSTO Investigators. Mortality reduction with accelerated tissue plasminogen activator is explained by early coronary patency (abstr). Circulation 1993;88:I-291.
Tiefenbrunn AJ, Sobel BE. Timing of coronary recanalization. Paradigms, paradoxes, and pertinence. Circulation 1992;85:2311–2315.
Weaver WD, Cerqueira M, Hallstrom AP, et al. for the MITI Project Investigators. Prehospital-initiated vs. hospital-initiated thrombolytic therapy. JAMA 1993;270:1211–1216.
GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.
Cooper RS, Simmons B, Castaner A, et al. Survival rates and prehospital delay during myocardial infarction among black persons. Am J Cardiol 1986;57:208–211.
Maynard C, Althouse R, Olsufka M, et al. Early versus late hospital arrival for acute myocardial infarction in the western Washington thrombolytic therapy trials. Am J Cardiol 1989;63:1296–1300.
Kereiakes DJ, Weaver WD, Anderson JL, et al. Time delays in the diagnosis and treatment of acute myocardial infarction: A tale of eight cities. Report from the Pre-hospital Study Group and the Cincinnati Heart Project. Am Heart J 1990;120:773–780.
Sharkey SW, Brunette DD, Ruiz E, et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989;262:3171–3174.
Kline EM, Smith DD, Martin JS, et al. In-hospital treatment delays in patients treated with thrombolytic therapy: A report of the GUSTO Time to Treatment Substudy (abstr). Circulation 1992;86:I-702.
National Heart Attack Alert Program Coordinating Committee, 60 Minutes to Treatment Working Group. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311–329.
Rogers WJ, Bowlby LJ, Chandra N, et al. Treatment of myocardial infarction in the United States (1990–1993): Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103–2114.
Jagger JD, Murray RG, Davies MK, Littler WA, Flint EJ. Eligibility for thrombolytic therapy in acute myocardial infarction. Lancet 1987;1:34–35.
Doorey AJ, Michelson EL, Topol EJ. Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises. JAMA 1992;268:3109–3114.
Ferguson JJ III. Meeting highlights. Circulation 1994;89:545–547.
Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversies. J AM Coll Cardiol 1990;16:223–231.
Collins R, for the ISIS Collaborative Group. Optimizing thrombolytic therapy of acute myocardial infarction: Age is not a contraindication (abstr). Circulation 1991;84:II-230.
LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993;342:759–766.
Foster DB, Dufendach JH, Barkdoll CM, Mitchell BK. Prehospital recognition of AMI using independent nurse/paramedic 12-lead ECG evaluation: Impact of in-hospital times to thrombolysis in a rural community hospital. Am J Emerg Med 1994;112:25–30.
Author information
Authors and Affiliations
Consortia
Additional information
This research was presented in part at the Annual Scientific Session, American College of Cardiology, Atlanta, Georgia, March 1994
Rights and permissions
About this article
Cite this article
Lambrew, C.T., Weaver, W.D., Rogers, W.J. et al. Hospital protocols and policies that may delay early identification and thrombolytic therapy of acute myocardial infarction patients. J Thromb Thrombol 3, 301–306 (1996). https://doi.org/10.1007/BF00133073
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00133073